CTLA4 and neoplasm: The CTLA-4 antibody drug ipilimumab, which has been listed, can produce strong anti-tumour effects in vivo, but antibody drugs are expensive and have strong immunogenic effect, while CTLA-4 activation antibody to the systemic immune system will cause irAEs in a variety of peripheral tissues [17, 18].